Amundi Has $429,000 Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Amundi boosted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 200.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,114 shares of the company's stock after acquiring an additional 15,431 shares during the period. Amundi owned 0.05% of Pacira BioSciences worth $429,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PCRX. PNC Financial Services Group Inc. increased its holdings in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after acquiring an additional 513 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after acquiring an additional 918 shares during the period. Caitlin John LLC grew its stake in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares in the last quarter. Global Alpha Capital Management Ltd. increased its holdings in shares of Pacira BioSciences by 5.7% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company's stock valued at $752,000 after purchasing an additional 2,160 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Remove Ads

Pacira BioSciences Price Performance

PCRX stock traded up $0.70 during trading on Monday, reaching $24.84. 1,032,975 shares of the company were exchanged, compared to its average volume of 909,408. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.24 and a beta of 0.86. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company has a 50-day moving average of $24.44 and a two-hundred day moving average of $19.61. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PCRX shares. HC Wainwright raised their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Needham & Company LLC raised their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences currently has an average rating of "Hold" and a consensus price target of $27.22.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.